Skip to main content

Milestone Pharmaceuticals Inc(MIST-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.6400
Day High1.7300
Open:1.6900
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Milestone Pharmaceuticals Inc

Select a category then submit the form to load news
GlobeNewswire
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
Tipranks
Milestone Pharmaceuticals Sets March 20 Call for 2025 Results and Business Update
GlobeNewswire
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
GlobeNewswire
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
GlobeNewswire
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tipranks
Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
Tipranks
Milestone Pharmaceuticals announces U.S. availability of cardamyst
GlobeNewswire
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Tipranks
Milestone Pharmaceuticals Secures $75M Non-Dilutive Royalty Financing
Tipranks
Milestone’s PSVT nasal spray MAA accepted by EMA
Tipranks
Milestone announces acceptance of MAA by EMA for etripamil nasal spray
GlobeNewswire
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Tipranks
Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval
Tipranks
Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST
GlobeNewswire
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
GlobeNewswire
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS), Milestone Pharmaceuticals (MIST) and Astria Therapeutics (ATXS)
Tipranks
Milestone Pharmaceuticals Reports Q3 2025 Financial Results
Tipranks
Milestone Pharmaceuticals Prepares for CARDAMYST Launch Amid Financial Growth
GlobeNewswire
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
GlobeNewswire
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
GlobeNewswire
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
Tipranks
Analysts Offer Insights on Healthcare Companies: Kala Pharmaceuticals (KALA) and Milestone Pharmaceuticals (MIST)
GlobeNewswire
Milestone® Pharmaceuticals to Present at Upcoming Conferences
Tipranks
TD Cowen Keeps Their Hold Rating on Milestone Pharmaceuticals (MIST)
Tipranks
Milestone Pharmaceuticals Advances CARDAMYST with FDA and Financial Boost
GlobeNewswire
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Tipranks
Analysts Offer Insights on Healthcare Companies: Kestra Medical Technologies Ltd. (KMTS) and Milestone Pharmaceuticals (MIST)
Tipranks
TD Cowen Sticks to Its Hold Rating for Milestone Pharmaceuticals (MIST)
Tipranks
Milestone Pharmaceuticals Announces Public Offering for $48.7M

Profile

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montr'al, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.